If your weight loss goals have taken a backward step, this simple device might be all you need to get back on track and shed ...
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...
The FDA is about to make it a lot harder to get cheap weight-loss drugs Jessica DeBenedetto has only been on compounded tirzepatide for a couple of weeks, but she already feels like it's a life ...
On December 19, 2024, FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly is tirzepatide’s patentholder and the ...
Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...
Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...
In October, NHS England proposed a phased rollout of tirzepatide. Under draft guidance from an independent committee at the National Institute for Health and Care Excellence, tirzepatide has been ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback